Cargando…
Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential
Claudin-low tumors are a highly aggressive breast cancer subtype with no targeted treatments and a clinically documented resistance to chemotherapy. They are significantly enriched in cancer stem cells (CSCs), which makes claudin-low tumor models particularly attractive for studying CSC behavior and...
Autores principales: | Knezevic, Jana, Pfefferle, Adam D., Petrovic, Ivana, Greene, Stephanie B., Perou, Charles M., Rosen, Jeffrey M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564359/ https://www.ncbi.nlm.nih.gov/pubmed/25746005 http://dx.doi.org/10.1038/onc.2015.48 |
Ejemplares similares
-
Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells
por: Rädler, Patrick D., et al.
Publicado: (2021) -
Targeting claudin‐4 enhances chemosensitivity in breast cancer
por: Luo, Yi, et al.
Publicado: (2020) -
MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2
por: Liu, Yang, et al.
Publicado: (2017) -
Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer
por: Nishiguchi, Yukiko, et al.
Publicado: (2019) -
Targeting claudin‐4 enhances chemosensitivity of pancreatic ductal carcinomas
por: Sasaki, Takamitsu, et al.
Publicado: (2019)